1. Home
  2. Sistema de Salut de Catalunya
  3. Vall d'Hebron Institut d'Oncologia – VHIO
  4. Articles científics - VHIO
  5. View Item

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma

To access the full text documents, please follow this link: https://hdl.handle.net/11351/13689

Author

BAURAIN, JEAN-FRANCOIS

Martelli, Serena

Arntz, Ramon

Savoia, Paola

MUÑOZ COUSELO, EVA

Berking, Carola

Other authors

Institut Català de la Salut

[Muñoz Couselo E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Berking C] Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. Comprehensive Cancer Center Erlangen—European Metropolitan Area of Nürnberg (CCC ER-EMN), Erlangen, Germany. Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Erlangen, Germany. [Baurain JF] Institut Roi Albert II, Cliniques Universitaires SaintLuc, Université Catholique de Louvain, Brussels, Belgium. Institute for Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium. [Martelli S, Arntz R] Sun Pharmaceutical Industries B.V., Hoofddorp, The Netherlands. [Savoia P] Department of Health Sciences, University of Eastern Piedmont, Novara, Italy

Vall d'Hebron Barcelona Hospital Campus

Publication date

2025-09-19T08:25:45Z

2025-09-19T08:25:45Z

2025-09



Share

Abstract

Secondary resistance; Locally advanced basal cell carcinoma

Resistencia secundaria; Carcinoma basocelular localmente avanzado

Resistència secundària; Carcinoma basocel·lular localment avançat

The BOLT study was sponsored and funded by Novartis; this analysis was funded by Sun Pharma. Medical writing and editorial support were funded by Sun Pharma Europe B.V.

Document Type

Article

Published version

Language

English

Subjects and keywords

Medicaments antineoplàstics - Ús terapèutic - Efectes secundaris; Carcinoma basocel·lular - Tractament; DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Carcinoma, Basal Cell; Other subheadings::Other subheadings::Other subheadings::/drug therapy; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents; Other subheadings::Other subheadings::Other subheadings::/adverse effects; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::carcinoma basocelular; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos

Publisher

Wiley

Related items

Journal of the European Academy of Dermatology and Venereology;39(9)

https://doi.org/10.1111/jdv.20629

Recommended citation

This citation was generated automatically.

Export

DIDL MARC MARC_CCUC METS OAI_DC ORE QDC RDF

Rights

Attribution-NonCommercial 4.0 International

http://creativecommons.org/licenses/by-nc/4.0/

This item appears in the following Collection(s)

Articles científics - HVH [3440]